Jim Cramer: Johnson & Johnson Will Do Well With Actelion
J&J has the potential to 'blow out' Actelion's high blood pressure drug, says Jim Cramer.
Johnson & Johnson (JNJ) - Get Report could do very well by acquiring Actelion and its drug for high blood pressure, but drug stocks are tenuous these days, said TheStreet's Jim Cramer.
